These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
504 related articles for article (PubMed ID: 22441145)
1. Transforming growth factor β and Ras/MEK/ERK signaling regulate the expression level of a novel tumor suppressor Lefty. Miyata N; Azuma T; Hozawa S; Higuchi H; Yokoyama A; Kabashima A; Igarashi T; Saeki K; Hibi T Pancreas; 2012 Jul; 41(5):745-52. PubMed ID: 22441145 [TBL] [Abstract][Full Text] [Related]
2. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1. Gysin S; Lee SH; Dean NM; McMahon M Cancer Res; 2005 Jun; 65(11):4870-80. PubMed ID: 15930308 [TBL] [Abstract][Full Text] [Related]
3. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells. Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520 [TBL] [Abstract][Full Text] [Related]
4. Oncogenic Ras blocks transforming growth factor-beta-induced cell-cycle arrest by degradation of p27 through a MEK/Erk/SKP2-dependent pathway. Schepers H; Wierenga AT; Eggen BJ; Vellenga E Exp Hematol; 2005 Jul; 33(7):747-57. PubMed ID: 15963850 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival. Ripple MO; Kalmadi S; Eastman A Breast Cancer Res Treat; 2005 Sep; 93(2):177-88. PubMed ID: 16187238 [TBL] [Abstract][Full Text] [Related]
6. Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Ellenrieder V; Hendler SF; Boeck W; Seufferlein T; Menke A; Ruhland C; Adler G; Gress TM Cancer Res; 2001 May; 61(10):4222-8. PubMed ID: 11358848 [TBL] [Abstract][Full Text] [Related]
7. TGF-beta3 regulates anchoring junction dynamics in the seminiferous epithelium of the rat testis via the Ras/ERK signaling pathway: An in vivo study. Xia W; Cheng CY Dev Biol; 2005 Apr; 280(2):321-43. PubMed ID: 15882576 [TBL] [Abstract][Full Text] [Related]
8. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors. Marampon F; Ciccarelli C; Zani BM Mol Cancer; 2006 Aug; 5():31. PubMed ID: 16899113 [TBL] [Abstract][Full Text] [Related]
9. Angiotensin II regulation of TGF-beta in murine mesangial cells involves both PI3 kinase and MAP kinase. Perlman A; Lawsin LM; Kolachana P; Saji M; Moore J; Ringel MD Ann Clin Lab Sci; 2004; 34(3):277-86. PubMed ID: 15487702 [TBL] [Abstract][Full Text] [Related]
10. The tumor suppressor KLF11 mediates a novel mechanism in transforming growth factor beta-induced growth inhibition that is inactivated in pancreatic cancer. Buck A; Buchholz M; Wagner M; Adler G; Gress T; Ellenrieder V Mol Cancer Res; 2006 Nov; 4(11):861-72. PubMed ID: 17114344 [TBL] [Abstract][Full Text] [Related]
11. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines. Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493 [TBL] [Abstract][Full Text] [Related]
12. KLF11 mediates a critical mechanism in TGF-beta signaling that is inactivated by Erk-MAPK in pancreatic cancer cells. Ellenrieder V; Buck A; Harth A; Jungert K; Buchholz M; Adler G; Urrutia R; Gress TM Gastroenterology; 2004 Aug; 127(2):607-20. PubMed ID: 15300592 [TBL] [Abstract][Full Text] [Related]
13. Restoration of IRF1-dependent anticancer effects by MEK inhibition in human cancer cells. AbuSara N; Razavi S; Derwish L; Komatsu Y; Licursi M; Hirasawa K Cancer Lett; 2015 Feb; 357(2):575-81. PubMed ID: 25497010 [TBL] [Abstract][Full Text] [Related]
14. p8 inhibits the growth of human pancreatic cancer cells and its expression is induced through pathways involved in growth inhibition and repressed by factors promoting cell growth. Malicet C; Lesavre N; Vasseur S; Iovanna JL Mol Cancer; 2003 Nov; 2():37. PubMed ID: 14613582 [TBL] [Abstract][Full Text] [Related]
15. Signal transduction of MEK/ERK and PI3K/Akt activation by hypoxia/reoxygenation in renal epithelial cells. Kwon DS; Kwon CH; Kim JH; Woo JS; Jung JS; Kim YK Eur J Cell Biol; 2006 Nov; 85(11):1189-99. PubMed ID: 16860436 [TBL] [Abstract][Full Text] [Related]
16. p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells. Ciccarelli C; Marampon F; Scoglio A; Mauro A; Giacinti C; De Cesaris P; Zani BM Mol Cancer; 2005 Dec; 4():41. PubMed ID: 16351709 [TBL] [Abstract][Full Text] [Related]
17. Increased expression of Nodal correlates with reduced patient survival in pancreatic cancer. Kong B; Wang W; Esposito I; Friess H; Michalski CW; Kleeff J Pancreatology; 2015; 15(2):156-61. PubMed ID: 25708930 [TBL] [Abstract][Full Text] [Related]
18. Extracellular signal-regulated kinase inhibition modulates rat annulus fibrosus cell response to interleukin-1. Wei Y; Zhi-Hong W; Gui-Xing Q; Bin Y; Jun C; Yi-Peng W Spine (Phila Pa 1976); 2013 Aug; 38(17):E1075-81. PubMed ID: 23680829 [TBL] [Abstract][Full Text] [Related]
19. Platelet-derived growth factor and transforming growth factor-beta modulate the expression of matrix metalloproteinases and migratory function of human airway smooth muscle cells. Ito I; Fixman ED; Asai K; Yoshida M; Gounni AS; Martin JG; Hamid Q Clin Exp Allergy; 2009 Sep; 39(9):1370-80. PubMed ID: 19522858 [TBL] [Abstract][Full Text] [Related]
20. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells. Komatsu N; Fujita Y; Matsuda M; Aoki K Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]